PMCHL1
Putative pro-MCH-like protein 1
Also known as: MCHL1_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for PMCHL1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
86 residues, UniProt reviewed canonical sequence.
>Q16048|PMCHL1
1 MLSQKPKKKH NFLNHGLSLN LVIKPYLALE GSVAFPAENG VQDTESTQEK RETGDEENSA
61 KFPVGRRDFD TLSCMLGRVY QSCWQVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PMCHL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PMCHL1 as an antibody target. Whether an autoantibody or antibody against PMCHL1 could matter depends on whether native PMCHL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PMCHL1 is annotated as secreted, so native PMCHL1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PMCHL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...